Long-term Impact of Infection With Novel Coronavirus (COVID-19) (LIINC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04362150|
Recruitment Status : Recruiting
First Posted : April 24, 2020
Last Update Posted : September 13, 2021
|Condition or disease|
LIINC is an observational, prospective study of individuals previously infected with SARS-CoV-2 who have recovered from acute illness. The overall objective of the study is to investigate the clinical consequences of SARS-CoV-2 infection. These include the pre-existence and development of medical conditions, measures of immune activation and inflammation, changes in immunologic function, and variability in host responses. There will be a specific focus on demographic differences including age, gender, and race.
Enrolled volunteers are seen at San Francisco General Hospital at baseline, monthly for 3 months and then every 3 months for up to 2 years. Visits include a detailed interview, saliva collection, and a blood draw. Baseline visits take approximately 90 minutes, and follow up visits take approximately 20-40 minutes. No personal identifiers are used for specimen bank samples.
|Study Type :||Observational|
|Estimated Enrollment :||800 participants|
|Official Title:||Long-term Impact of Infection With Novel Coronavirus (LIINC): An Observational Study|
|Actual Study Start Date :||April 21, 2020|
|Estimated Primary Completion Date :||December 31, 2022|
|Estimated Study Completion Date :||December 31, 2022|
COVID-19 positive, recovered
Individuals with positive test for COVID-19 who have recovered from acute infection (21 days after symptom onset + improvement in symptoms + resolution of fever for 72 hours without fever reducing medicines).
- Participant age [ Time Frame: Baseline visit ]The median age of study participants at enrollment.
- Participant sex [ Time Frame: Baseline visit ]The proportion of men and women participating in the baseline visit.
- Participant race/ethnicity [ Time Frame: Baseline visit ]The proportion of participants from each demographic group.
- Proportion of participants previously hospitalized. [ Time Frame: Baseline visit ]The proportion of participants who were previously hospitalized.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04362150
|Contact: Rebecca Hoh, MS, RD||415-476-4082 ext email@example.com|
|Contact: Michael J Peluso, MDfirstname.lastname@example.org|
|United States, California|
|Zuckerberg San Francisco General Hospital (ZSFG)||Recruiting|
|San Francisco, California, United States, 94110|
|Contact: Steven G Deeks, MD 415-206-3103 Steven.Deeks@ucsf.edu|
|Contact: Rebecca Hoh 415-476-4082 ext 139 Rebecca.Hoh@ucsf.edu|
|Principal Investigator: Steven G Deeks, MD|
|Principal Investigator:||Steven Deeks, MD||University of California, San Francisco|